APOA1 and schizophrenia: Research in schizophrenia has shown a notable decrease in APOA-I across five tissues (cerebrospinal fluid, brain, liver, red blood cells, and serum) in patients, potentially contributing to their heightened risk of metabolic disorders (Huang et al., 2008).